Hepatomegaly and cholestasis as primary clinical manifestations of an AL-kappa amyloidosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 8, 1999, Pages 921-925

  Mohr, Anja ^a,c   Miehlke, Stephan ^b   Klauck, Sabine ^a   Röcken, Christoph ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c NONE   (Germany)

Author keywords

Amyloidosis; Cholestasis; Hepatomegaly; Renal failure

Indexed keywords

AMYLOID A PROTEIN; LIVER ENZYME;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CHOLESTASIS; ECHOCARDIOGRAPHY; HEART FAILURE; HEPATOMEGALY; HUMAN; KIDNEY DISEASE; LIVER BIOPSY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0032808121     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199908000-00020     Document Type: Article

References (24)

1. 1 Isobe T, Osserman EF. Patterns of amyloidosis and their association with plasma cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Engl J Med 1974; 290:473-477.
2. 2 Glenner GG. Amyloid deposits and amyloidosis: the beta-fibrilloses. N Engl J Med 1980; 302:1283-1292.
3. 3 Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA 1992; 268:2946-2951.
4. 4 Skinner M, Anderson JJ, Simms R, Falk R, Wang M, Libbey CA, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100:290-298.
5. 5 Hawkins PN. Amyloidosis. In: Myeloma, Biology and Management. Malpas JS, Bergsagel DE, Kyle RA (editors). Oxford: Oxford University Press; 1995. pp. 481-482.
6. 6 Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88:2801 -2806.
7. 7 Kyle RA, Gertz MA, Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Seminars in Hematology 1995; 32:45-59.
8. 8 Gertz MA, Kyle RA. Hepatic amyloidosis (primary (AL), immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85:73-80.
9. 9 Peters RA, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R, et al. Primary amyloidosis and severe intrahopatic cholestatic jaundice. Gut 1994; 35:1322-1325.
10. 10 Greipp PR. Amyloidosis (AL): an approach to early diagnosis. Arch Int Med 1984; 11:2145.
11. 11 Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prodnisone versus colchicine. Am J Med 1985; 79:708-715.
12. 12 Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77:257-262.
13. 13 Kyle RA, Linos A, Beard M, Linke RP, Gertz MA, O'Fallon WM, el al. Incidence and natural history of primary systemic amyloidosis in olmsted county, Minnesota, 1950 through 1989. Blood 1992; 79:1817-1822.
14. 14 Gertz MA, Kyle RA. Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology 1997, 25:118-121.
15. 15 Zeijen RNM, Sels JP, Flendrig JA, Arends JW. Portal hypertension and intrahepatic cholestasis in hepatic amyloidosis. Netherlands J Med 1991; 38:257-261.
16. 16 Dohmen K, Nagano M, Iwakiri R, Yamano Y, Kikuchi Y, Mizoguchi M, et al. A case of prominent hepatic cholestasis developing to hepatic failure in lambda-AL amyloidosis. Gastroenterol Jap 1991; 26:376-381.
17. 17 Yamamoto T, Maeda N, Kawasaki H. Hepatic failure in a case of multiple myeloma-associated amyloidosis (Kappa-AL). J Gastroenterol 1995; 30:393-397.
18. 18 Tada S, lida M, Yao T, Kitamoto T, Yao T, Fujishima M, et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34:1412-1417.
19. 19 Baldewijns M, Ectors N, Verbeeck G, Janssens J, De Schepper J, Ponette E, et al. Intermittent subobstruction and cholestasis as complications of duodenal amyloid tumors. Gastroenterol Clin Biol 1995; 19:218-221.
20. 20 Gertz MA, Kyle RA, Greipp PR, Katzmann JA, O'Fallon M. Beta-2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med 1990; 89:609-614.
21. 21 Majolino I, Marceno R, Pecorado G, Scime R, Vasta R, Liberti G, et al. High-dose therapy and autologous transplantation in amyloidosis AL. Haematologica 1993; 78:68-71.
22. 22 Moreau P, Milpied N, de Faucal P, Petit T, Herbouiller P, Bataille R, er al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996, 87:3063-3064.
23. 23 Hall R, Hawkins PN. Cardiac transplantation for AL-amyloidosis. BMJ 1994; 309:1135-1137.
24. 24 Röcken C, Saeger W, Linke RP. Portal amyloid. Novel amyloid deposits in gastrointestinal veins? Arch Pathol Lab Med 1996; 120:1044 -1051.